Gout: Suboptimal Management a Continuing Problem

Although urate-lowering drugs form the cornerstone of gout therapy, there are only three oral medications currently available in the United States, and all have significant limitations.

Related Keywords

United States ,Milan ,Lombardia ,Italy ,San Diego ,California ,Boston ,Massachusetts ,Tuhina Neogi ,Roberta Terkeltaub ,Sarak Tedeschi ,University Of California ,Va Medical Center ,Harvard Medical School ,American College Of Rheumatology ,European Congress ,American College Of Physicians ,Boston Medical Center ,Boston Medical ,Third World ,Gout ,Clinical Guidelines ,Guidelines ,Renal Disease ,Kidney Disease ,Kidney Disorder ,Renal Disorder ,Ephropathy ,Drug Development ,Drug Discovery ,Drug Pipeline ,Drug Development Pipeline ,Kidneys ,Adverse Effects ,Side Effects ,Heart ,Primary Care ,Adherence ,Dherence To Medication Issues For Patients ,Compliance ,Rug Compliance ,Treatment Adherence ,Anticoagulation Therapy ,Anticoagulant ,